Latest News

FDA Awards Breakthrough Therapy Designation to Novel HER2-Activating NSCLC Therapy
FDA Awards Breakthrough Therapy Designation to Novel HER2-Activating NSCLC Therapy

February 27th 2024

The FDA has granted a breakthrough therapy designation to BAY 2927088 for the treatment of non-small cell lung cancer harboring HER2-activating mutations.

Husain Evaluates Real-World Evidence for Immunotherapy in Stage III NSCLC
Husain Evaluates Real-World Evidence for Immunotherapy in Stage III NSCLC

February 24th 2024

Roundtable Roundup: Stage IIB Lung Cancer
Roundtable Roundup: Stage IIB Lung Cancer

February 22nd 2024

Velcheti Addresses Promising Data with Repotrectinib in ROS1+ NSCLC
Velcheti Addresses Promising Data with Repotrectinib in ROS1+ NSCLC

February 20th 2024

Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment
Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment

February 19th 2024

More News